
Suven Pharma Q2 profit rises 31% to ₹97 cr.
The Hindu
Suven Pharmaceuticals on Saturday posted a 31% increase in its consolidated net profit to ₹97 crore for the second quarter ended September 30. Revenue from operations rose to ₹301 crore for the quarte
Suven Pharmaceuticals on Saturday posted a 31% increase in its consolidated net profit to ₹97 crore for the second quarter ended September 30.
Revenue from operations rose to ₹301 crore for the quarter under review, as against ₹237 crore in the year-earlier period, Suven Pharmaceuticals said in a regulatory filing.
The COVID-19 pandemic continues to impact the business and research in India and its wholly owned subsidiary, Suven Pharma Inc. USA, it noted.

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












